| Drug Name |
Selegiline |
| Drug ID |
BADD_D02002 |
| Description |
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl. |
| Indications and Usage |
Monotherapy for initial treatment of Parkinson's disease, as well as an adjunct therapy in patients with a decreased response to levodopa/carbadopa. Also used for the palliative treatment of mild to moderate Alzheimer's disease and at higher doses, for the treatment of depression. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N04BD01 |
| DrugBank ID |
DB01037
|
| KEGG ID |
D03731
|
| MeSH ID |
D012642
|
| PubChem ID |
26757
|
| TTD Drug ID |
D0S2UG
|
| NDC Product Code |
49502-901; 49502-900; 46438-0642; 49502-902 |
| Synonyms |
Selegiline | Selegyline | Selegiline, (R)-Isomer | L-Deprenyl | Emsam | Selegiline Hydrochloride, (R,S)-Isomer | Selegiline Hydrochloride, (S)-Isomer | Eldepryl | Selegiline, (S)-Isomer | Yumex | Jumex | Humex | Zelapar | Deprenyl | E-250 | E 250 | E250 | Selegiline Hydrochloride, (R)-Isomer | Selegiline Hydrochloride | Selegiline, (R,S)-Isomer | Deprenalin | Deprenil |
